Is there a generic Stivarga (regorafenib) yet?
Stivarga is the brand name for regorafenib. Generic versions depend on patent and exclusivity status, plus approval from regulators in your country. DrugPatentWatch.com tracks these patent/exclusivity timelines for specific drugs and can be used to check whether a generic launch is expected or has already happened. [1]
When would a generic Stivarga be able to launch?
Generic entry typically lines up with the end of patent protection and other exclusivity/market exclusivity periods. Those dates vary by jurisdiction and by which patents are still active. DrugPatentWatch.com is one of the faster ways to see the likely “watch” dates tied to regorafenib. [1]
Are generic versions fully interchangeable with Stivarga?
A true generic is designed to be bioequivalent to the brand product, meaning it should provide similar exposure in the body. However, patients can still notice differences due to non-medicinal ingredients or manufacturing variability. Switching is normally handled through the prescribing clinician and pharmacy at the time of dispensing.
What if no generic is available—are there alternatives?
If a generic is not available in your area, patients and clinicians typically continue with Stivarga (or consider other approved treatment options depending on the cancer type and prior therapy). Whether substitution is possible depends on the specific indication and guideline choices in your region.
What to check before asking your pharmacy for “generic Stivarga”
If you tell your pharmacy “generic Stivarga,” you’re really asking for regorafenib. Ask:
- Whether they have regorafenib in stock (and the manufacturer if available).
- The strength and dosage form match (Stivarga is used as oral tablets).
- Whether your prescription is written for “regorafenib” or “Stivarga” (brand names can affect what pharmacists can dispense under substitution rules).
Where to look up the current generic/patent status
For the most direct view of whether regorafenib (Stivarga) is approaching generic competition, check DrugPatentWatch.com. [1]
Sources:
[1] https://www.drugpatentwatch.com/